Precision Medicine for Pediatric Glioma and NF1-Associated Tumors: The Role of Small Molecule Inhibitors

Pediatric gliomas encompass the most common brain tumor in children and are subdivided into pediatric low-grade gliomas (pLGGs) and pediatric high-grade gliomas (pHGGs). The era of molecular diagnosis has shifted the treatment paradigms and management of these patients. RAS/MAPK pathway alterations...

Full description

Bibliographic Details
Published in:	Current Oncology
Main Authors:	Samuele Renzi, Julie Bennett, Nirav Thacker, Chantel Cacciotti
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Subjects:	glioma MEK inhibitor BRAF inhibitor Pan-RAF inhibitor FGFR inhibitor TRK inhibitor
Online Access:	https://www.mdpi.com/1718-7729/32/5/280

Similar Items

Canadian Consensus for Treatment of BRAF <i>V600E</i> Mutated Pediatric and AYA Gliomas
by: Craig Erker, et al.
Published: (2024-07-01)

ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells
by: Giulia Cesi, et al.
Published: (2017-06-01)

REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION
by: I. V. Samoylenko, et al.
Published: (2017-11-01)

Incidence of Ophthalmological Complications in NF-1 Patients Treated with MEK Inhibitors
by: Lena Hummel, et al.
Published: (2024-05-01)

Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review
by: Nina Yu, et al.
Published: (2024-12-01)

Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases
by: Matthew Smith-Cohn, et al.
Published: (2019-12-01)

A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01
by: Sébastien Perreault, et al.
Published: (2019-12-01)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma
by: Ernesto Rossi, et al.
Published: (2023-01-01)

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
by: Dahlia Fedele, et al.
Published: (2024-01-01)

BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways
by: Peng Yue, et al.
Published: (2019-01-01)

Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma
by: JIANG Jianyun, YING Hongmei
Published: (2022-05-01)

Continuous response despite reduced dose of trametinib as single agent in an adolescent with a relapsed disseminated pediatric low-grade glioma KIAA1549-BRAF fusion positive: a case report and review of the literature
by: Serafin Castellano-Damaso, et al.
Published: (2024-05-01)

Treatment of Advanced Melanoma: Past, Present and Future
by: Taku Fujimura, et al.
Published: (2020-09-01)

Beneficial effects of vemurafenib on craniopharyngioma carrying BRAF-V600E mutation
by: WANG Xi, YE Ting, NIE Min, WU Xueyan, MAO Jiangfeng
Published: (2024-06-01)

The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies
by: Saber Imani, et al.
Published: (2024-11-01)

Comparison of the efficacy of rechallenge with anti-PD-1 antibody monotherapy and BRAF/MEK inhibitor in advanced malignant melanoma: A single-center, retrospective cohort study
by: Ken Horisaki, et al.
Published: (2025-04-01)

Efficiency of B-RAF-/MEK-inhibitors in B-RAF mutated Ameloblastoma: Case report and review of literature
by: Reinhard Büttner, et al.
Published: (2023-12-01)

Clinical research progress in the treatment of <italic>BRAF</italic> V600 mutation-positive advanced melanoma
by: Jianyun JIANG, et al.
Published: (2022-05-01)

Treatment patterns of melanoma by BRAF mutation status in the USA from 2011 to 2017: a retrospective cohort study
by: Shweta Shah, et al.
Published: (2019-12-01)

FGFR1 Expression and Role in Migration in Low and High Grade Pediatric Gliomas
by: Naomi Egbivwie, et al.
Published: (2019-03-01)

Practical application of precision oncology in adult onset craniopharyngiomas
by: Chandrima Biswas, et al.
Published: (2024-11-01)

The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysis
by: Mohammad Amin Habibi, et al.
Published: (2025-06-01)

Cutaneous adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis
by: Junhui Qian, et al.
Published: (2024-12-01)

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives
by: Dugan MM, et al.
Published: (2024-07-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
by: Eva Marie Erfurth, et al.
Published: (2024-12-01)

PEDIATRIC LOW-GRADE GLIOMAS AND MEK INHIBITORS – CASE REPORT
by: Urša Jenko, et al.
Published: (2023-10-01)

BRAF/MEK inhibitors use for pediatric gliomas; real world experience from a resource-limited country
by: Dima Abu Laban, et al.
Published: (2024-09-01)

Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer
by: Eunyoung Tak, et al.
Published: (2025-03-01)

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study
by: Blessie Elizabeth Nelson, et al.
Published: (2024-03-01)

Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg
by: Andrea Forschner, et al.
Published: (2025-02-01)

Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trialResearch in context
by: Tatsunori Shimoi, et al.
Published: (2024-03-01)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
by: Nakul Dar, et al.
Published: (2023-08-01)

Molecular Susceptibility and Treatment Challenges in Melanoma
by: Kiran Kumar Kolathur, et al.
Published: (2024-08-01)

Eruptive Melanocytic Nevi in the Setting of Encorafenib, Cetuximab, and Binimetinib Combination Therapy: A Case Report
by: Karen Lam, et al.
Published: (2024-05-01)

The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
by: Jimin Yuan, et al.
Published: (2020-08-01)

Patient preferences for stages II–IV melanoma treatments in the UK: results from a cross-sectional study
by: Luis Vaz, et al.
Published: (2025-12-01)

Therapeutic Potential of Black Pepper Compound for BRaf Resistant Melanoma
by: Neel M. Fofaria, et al.
Published: (2017-11-01)

Global trends and emerging insights in BRAF and MEK inhibitor resistance in melanoma: a bibliometric analysis
by: Jianhao Bai, et al.
Published: (2025-01-01)

A Mathematical Model for the Treatment of Melanoma with the BRAF/MEK Inhibitor and Anti-PD-1
by: OPhir Nave, et al.
Published: (2022-12-01)

Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
by: Francisco Meraz-Torres, et al.
Published: (2024-01-01)